VCEL - Vericel Corporation
| Previous Close | 16.26 |
| Open | 16.23 |
| Bid | 16.24 x 1000 |
| Ask | 16.90 x 2200 |
| Day's Range | 16.15 - 16.98 |
| 52 Week Range | 8.95 - 21.01 |
| Volume | 570,460 |
| Avg. Volume | 639,945 |
| Market Cap | 728.51M |
| Beta (3Y Monthly) | 1.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.20 |
| Earnings Date | Nov 6, 2017 - Nov 10, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.75 |
- GlobeNewswire•16 days ago
Vericel to Present at Needham Healthcare Conference
CAMBRIDGE, Mass., April 03, 2019 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced.
- GlobeNewswire•18 days ago
Market Trends Toward New Normal in Verizon Communications, Digital Turbine, Vericel, Capstead Mortgage, Paratek Pharmaceuticals, and CryoPort — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
- Simply Wall St.•last month
Our Take On Vericel Corporation’s (NASDAQ:VCEL) CEO Salary
Nick Colangelo has been the CEO of Vericel Corporation (NASDAQ:VCEL) since 2013. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that,Read More...
- Zacks•last month
What Makes Vericel (VCEL) a New Buy Stock
Vericel (VCEL) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire•2 months ago
Vericel to Present at Multiple Upcoming Investor Conferences
CAMBRIDGE, Mass., March 04, 2019 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of VCEL earnings conference call or presentation 26-Feb-19 1:30pm GMT
Q4 2018 Vericel Corp Earnings Call
Motley Fool•2 months agoVericel Corp (VCEL) Q4 2018 Earnings Conference Call Transcript
VCEL earnings call for the period ending December 31, 2018.
- Zacks•2 months ago
Vericel (VCEL) Tops on Q4 Earnings & Sales, Stock Up
Vericel (VCEL) beat estimates for earnings as well as revenues in fourth-quarter 2018. Shares up in pre-market trading.
- GlobeNewswire•2 months ago
Vericel Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Full-Year 2019 Financial Guidance
Record Quarterly Product Revenues of $31.3 Million Represent a 41% Increase Over Fourth Quarter 2017 Full-Year 2018 Product Revenues of $90.9 Million Conference Call Today at.
- Zacks•2 months ago
What's in Store for Vericel (VCEL) This Earnings Season?
On Vericel's (VCEL) fourth-quarter conference call, investor focus will be on the sales figures of the company's two approved medicines -- MACI and Epicel.
- GlobeNewswire•2 months ago
Vericel to Participate in Multiple Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 20, 2019 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced.
- GlobeNewswire•2 months ago
Vericel to Report Fourth-Quarter 2018 Financial Results on February 26, 2019
CAMBRIDGE, Mass., Feb. 12, 2019 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced.
- GlobeNewswire•3 months ago
Vericel to Present at the 21st Annual Needham Growth Conference
CAMBRIDGE, Mass., Jan. 11, 2019 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced.
- Zacks•3 months ago
Bull or Bear: Your Investment Strategy for 2019
Whether you're a bull or a bear, it may be a good idea to go defensive about now.
- GlobeNewswire•3 months ago
Vericel Reports Publication of Outcomes Data From 954 Burn Patients Treated With Epicel in the Journal of Burn Care and Research
Vericel Corporation (VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the publication of outcomes data for 954 burn patients treated with Epicel® (cultured epidermal autografts) in the Journal of Burn Care and Research. The results demonstrated an increased survival rate for patients treated with Epicel when compared to results reported for patients in the National Burn Repository with comparable burns. Epicel is a permanent skin replacement produced from patients’ own cells and indicated for use in adult and pediatric patients who have deep dermal or full thickness burns comprising a total body surface area (TBSA) greater than or equal to 30%.
- Zacks•3 months ago
Zacks.com featured highlights include: Alteryx, Vericel, Mitek and Materialise
Zacks.com featured highlights include: Alteryx, Vericel, Mitek and Materialise
- Zacks•4 months ago
4 Stocks With Recent Price Strength to Maximize Your Gains
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
- Zacks•4 months ago
Has Vericel (VCEL) Outpaced Other Medical Stocks This Year?
Is (VCEL) Outperforming Other Medical Stocks This Year?
- Zacks•4 months ago
5 Nasdaq Composite Stocks That Braved the Index's Bloodbath
Despite a plummeting Nasdaq Composite, a few companies have survived the turbulence because of their internal strengths.
- Zacks•4 months ago
4 Healthcare Stocks That Popped More Than 100% in 2018
Players in the Healthcare sector gained from aging population, expanding government business, technological investment, strong demand for its product and services and industry consolidation.
- Zacks•4 months ago
Zacks.com featured highlights include: TEGNA, Vericel, Mobile Mini and Splunk
Zacks.com featured highlights include: TEGNA, Vericel, Mobile Mini and Splunk
- Zacks•4 months ago
4 Best Stocks That Flaunt Superb Earnings Acceleration
Studies show that a majority of successful stocks see acceleration in earnings before an uptick in the stock price.
- Insider Monkey•4 months ago
Do Hedge Funds Love Vericel Corp (VCEL)?
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 7% during October and average hedge fund losing about 3%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by about […]
Zacks•4 months agoVericel (VCEL) Flat As Market Sinks: What You Should Know
Vericel (VCEL) closed the most recent trading day at $17.10, making no change from the previous trading session.
